Recent Articles:
ImmunoCellular (IMUC) Accelerating ICT-107 Clinical Trial Enrollment for Glioblastoma
Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike other cancer treatment companies, such as Dendreon (NASDAQ: DNDN), Oncothyreon (NASDAQ: ONTY) , IMUC is developing
Amarantus (AMBS) Licenses Parkinson’s Disease Biomarker Test from Power3
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ:
Immunocellular Therapeutics (IMUC): Targeting Cancer Stem Cells
Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike similar companies, such as ImmunoGen Inc. (NASDAQ: IMGN) and Dendreon Corp. (NASDAQ: DNDN), IMUC is developing
NFL Veterans Support Amarantus BioSciences’ Traumatic Brain Injury Research
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ:
ALR Technologies (ALRT): Penny Stock, Recent FDA Clearance, Enormous Potential
ALR Technologies Inc. (OTCBB: ALRT), an innovative medical device company, offers a unique software solution aimed at improving patient adherence to care plans in the diabetes industry working alongside companies like Abbott Laboratories (NYSE: ABT)
Amarantus (AMBS) CEO Gerald Commissiong Featured in Interview
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ:
Cardium (CXM) Inks First Marketing & Distribution Agreement for Excellagen(TM)
Cardium Therapeutics (Amex: CXM), a developer and acquirer of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies
Amarantus (AMBS) Updates Shareholders on Expanded Corporate Strategy
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ:
Cardium (CXM) and SourceOne Global Partners in Nutritional Supplement and Medical Foods Market
Cardium Therapeutics (NYSE Amex: CXM), a developer and acquirer of innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, like companies such as Nutraceutical
MabCure (MBCI): A Revolutionary Improvement to a Proven Cancer Technology
MabCure Inc. (PINK SHEETS: MBCI) is a biotechnology company focused on changing the perception that cancer is an incurable disease. Unlike Dendreon Corporation (NASDAQ: DNDN) or Generex Biotechnology Corporation (PINK SHEETS: GNBT), the company is
500 Million or 1 in 10 Adults Will have Diabetes by 2030
ALR Technologies Inc. (OTCBB: ALRT), developer of the revolutionary Health-e-Connect system, operating in the telehealth industry alongside companies like American Medical Alert (NASDAQ: AMAC) and Verizon (NYSE: VZ), could dramatically change the way diabetes is
Cardium (CXM) Launches MedPodium Neo-Energy(TM) and Neo-Carb Bloc(TM)
Cardium Therapeutics (NYSE Amex: CXM), a developer and acquirer or new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, like companies